Vor Biopharma
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Vor Biopharma sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Vor Biopharma: 6 sponsored US clinical trials, 2 recruiting.
Vor Biopharma sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 3 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Sjogren's Disease, with 1 trials.
Upper-quartile sponsor footprint
Vor Biopharma sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
NCT05984199
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
NCT05306574
A Long-term Follow-up Study of Patients Who Received VOR33
NCT05309733
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
NCT04849910
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Vor Biopharma pipeline
2 recruiting of 6 indexed (33% open).
Phase mix: 3 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Primary Sjogren's Disease (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vor Biopharma: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Vor Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Vor Biopharma page
6 registered trials is a research-attention snapshot, not an endorsement of Vor Biopharma or any single study.
- 2 of Vor Biopharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary Sjogren's Disease is the condition Vor Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Sjogren's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vor Biopharma pipeline card: 6 registered trials from official public datasets.Report a data error.